Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wednesday will be the day to be in RPC!
Watch and learn. This run ain't over!
I have a feeling we ain't seen nothin' yet on RPC. This thing can run much higher IMHO.
RPC is close to putting BioModa out of business. I hope you realize that. No need for Biomoda's test when RPCs can already do what Biomoda has been promising. If RPC gets validation and the same type of lung cancer approval they got in Canada, Biomoda is done. You get that right? Do your due dillegence. Read all the biomoda/rpc articles start with this one:
http://www.benzinga.com/press-releases/10/12/c725669/biotech-breakout-shares-continue-rising
"Buncha poor weak traders on I hub?"
Why do you keep gracing us losers with your presence?
Then again, looking back through some of your posts, it appears your track record well..
Let's just leave it at that.
Biomed rocks! I've made tons more money since Havrilla left to "start and manage his own hedge fund."
What happened to that hedge fund I wonder? Either it didn't work out or they are pumping stocks with it on his new site and shorting once the run up is done with the help of Timothy Sykes.
All those buys are close buds now.
At the end of the day its all about the score and the tabulations speak for themselves and I'm happy going to the bank with my profits.
It was a biomedreports play for maybe Crutch?
RPC - Radient Pharmaceuticals chart
Latest RPC technical analysis video. Just got notified it was posted to youtube via my susbscription!
You've been callin' it PJ. How far you think this thing goes?
Yeah RPC, it closed at the high of day and is getting some after hours hits at $1.35!
More news expected from RPC according to the source that put the spotlight on the stock during the holidays.
Thing has been a monster with a $4 price target short term!
Too bad. :(
Huge run by this stock doesn't appear anywhere near done. More rumors about the company put out today.
More like Goodbye Adam Feuerstine. RPC was a monster again today.
RPC is a monster and it is set to have another up week! Thanks for posting that.
Tweet from news source about RPC
BioMedReports tweeted this:
$RPC shares starting to rise from session lows on big block buys. Big news expected on multiple fronts starting Monday.
I just checked and someone is sitting on the RPC bid with 150K shares. This must be big news coming- as was predicted.
Someone sitting with 150K on the bid! Must be expecting big news.
Update RPC shares starting to rise again
tweet from biomedreports: $RPC shares starting to rise on big block buys in anticipation of next week's big news. about 1 minute ago · reply
RPC starting rise again!
biomedreports tweet: $RPC shares starting to rise on big block buys in anticipation of next week's big news. about 1 minute ago
Agreed. With big news pending next week, it should not be problem. Up from here. It's good to see that it held well regardless.
It's only 2 cents from breaking resistance. Then look out!
I was sure it was gonna close at $1.03 the way it was running.
Lots of rumors about Radient Pharmaceuticals. Stock has been on fire lately.
Here is latest analyst report and video with information-- expecting big move here next week!
http://www.cpreports.com/?p=738
Is ILNS frinally starting to bounce up off the bottom? Looks like it. Like the way the stock has been doin' it's thang lately.
So much volume and trading activity on this stock. Is it ready to pop or what?
Video: RPC Chart
Plus Fundamental Analysis
http://www.youtube.com/watch?v=6CllYmByrYQ
New Techinical Analysis Video: RPC!
http://www.youtube.com/watch?v=6CllYmByrYQ
RPC News!
Slow holiday season sees increased activity for Radient Pharmaceuticals
http://www.tradingmarkets.com/news/stock-alert/rpc_slow-holiday-season-sees-increased-activity-for-radient-pharmaceuticals-1390728.html
One stock that has found activity during the holiday season, generally considered one of the slowest times in on Wall Street, has been Radient Pharmaceuticals Corporation (AMEX: RPC | PowerRating), the big board listed micro-cap headquartered in Tustin, California is anticipating a debt to equity
swap that could strengthen the company if approved by the NYSE Amex on January 6th.
RPC's shares have been climbing from near 52-week lows
as investors have learned that the company is in position to eliminate up to $32,789,322 in liabilities, made up mostly of derivative liabilities and convertible notes.
"Based upon all of these liabilities being eliminated, RPC would then have approximately $22,130,106 in total shareholder equity," explained Douglas MacLellan, CEO of the company.
Both shareholders and debt holders agreed to convert the company's debt at RPC's annual meeting given the company's strong re-positioning in the marketplace including two recent moves involving its subsidiary Jade Pharmaceuticals, which is located in Shenzhen, China.
Those spin-off maneuvers involving Jade Pharmaceuticals and the company's CIT technology have also put the company in position to increase value and market cap significantly, according to MacLellan.
"This is something that the media has not really focused a great deal of attention on so far, but we anticipate that these two key transactions could bring as much as $80 million in additional value to the RPC shareholders in 2011."
The company's resources are concentrated in area of In Vitro Diagnostic Cancer Tests which have been clinically proven to detect multiple forms of cancer at very early stages, but like most biotechs who spent a great deal of money preparing their product for market, debt has been a heavy burden. It appears that is all about to change thanks to the forward thinking plans and vision of the leadership and shareholders.
The company, whose market cap stands at only $33.4 million, is vastly undervalued when compared to most of its competitors, but shares should feel the impact of these developments. Several analysts feel that converting the debt and spinning off the Chinese operations eliminates much of the risk associated with the stock. With a 12-month price target of $4 per share, Radient Pharmaceuticals appears on our list as one to own in 2011.
RPC NEWS... Slow holiday season sees increased activity for Radient Pharmaceuticals
http://www.tradingmarkets.com/news/stock-alert/rpc_slow-holiday-season-sees-increased-activity-for-radient-pharmaceuticals-1390728.html
One stock that has found activity during the holiday season, generally considered one of the slowest times in on Wall Street, has been Radient Pharmaceuticals Corporation (AMEX: RPC | PowerRating), the big board listed micro-cap headquartered in Tustin, California is anticipating a debt to equity
swap that could strengthen the company if approved by the NYSE Amex on January 6th.
RPC's shares have been climbing from near 52-week lows
as investors have learned that the company is in position to eliminate up to $32,789,322 in liabilities, made up mostly of derivative liabilities and convertible notes.
"Based upon all of these liabilities being eliminated, RPC would then have approximately $22,130,106 in total shareholder equity," explained Douglas MacLellan, CEO of the company.
Both shareholders and debt holders agreed to convert the company's debt at RPC's annual meeting given the company's strong re-positioning in the marketplace including two recent moves involving its subsidiary Jade Pharmaceuticals, which is located in Shenzhen, China.
Those spin-off maneuvers involving Jade Pharmaceuticals and the company's CIT technology have also put the company in position to increase value and market cap significantly, according to MacLellan.
"This is something that the media has not really focused a great deal of attention on so far, but we anticipate that these two key transactions could bring as much as $80 million in additional value to the RPC shareholders in 2011."
The company's resources are concentrated in area of In Vitro Diagnostic Cancer Tests which have been clinically proven to detect multiple forms of cancer at very early stages, but like most biotechs who spent a great deal of money preparing their product for market, debt has been a heavy burden. It appears that is all about to change thanks to the forward thinking plans and vision of the leadership and shareholders.
The company, whose market cap stands at only $33.4 million, is vastly undervalued when compared to most of its competitors, but shares should feel the impact of these developments. Several analysts feel that converting the debt and spinning off the Chinese operations eliminates much of the risk associated with the stock. With a 12-month price target of $4 per share, Radient Pharmaceuticals appears on our list as one to own in 2011.
RPC with $15 price target?!
There are rumors of a new analyst report hitting the news wires tomorrow morning. That's why RPC shares are going back up from session lows of $.79.
Look for a strong close!
There are rumors of a new analyst report hitting the news wires tomorrow morning. That's why RPC shares are going back up. Look for a strong close!
If Sykes really thinks this is a pump then he needs to get his subcribers to jump in and short RPC.
C'Mon Timmy.
Have your minions join you and all the other shorts that are getting fried at RPC. LOL
Do your homework for once.
I agree. I think the RPC stock is looking for any excuse to POP near the end of the day. Especially if the markets keep creeping up to a green close. Huge winner here aleady, but its like the energizer bunny. Going higher in anticipation of Jan 6th news event!
See video if you haven't--
Very bullish development here as this time the shorts are being squeezed nice and slowly. These shorts can't wait out the days between now and January 6th Amex approval. They are gonna have to cover. When they do.. BOOM!
I agree with you. I think this thing will only keep trading higher until January 6th. did you read the interview with the CEO?
http://finance.yahoo.com/news/Interview-With-the-CEO-of-iw-192171574.html?x=0&.v=1
Agreed. All those shorts are slowly being squeezed here. Stock now has support at $.97 -- 14-3 Day Raw Stochastic at 80%. Nice bullish flag forming here. I think this afternoon, the stock explodes up again. Keep an eye on it.
ILNS up huge!
RPC up another 20% - short squeeze coming
Ceo says big revenues, positive developments pending.
http://finance.yahoo.com/news/Interview-With-the-CEO-of-iw-192171574.html?x=0&.v=1
This stock has been a monster lately and with debt-to-equity approval coming from AMEX on January 6th, it's just gonna keep trading higher, IMHO.